The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma.
Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
Protocol Amendment History
20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2025-10-20; most recent amendment 2026-07-23.
Status change: Not Yet Recruiting → Recruiting2025-10-23